[1] Scheltens P, Strooper BD, Kivipelto M, et al. Alzheimer's disease[J]. The Lancet, 2021, 397: 1577-1590. [2] Bournazos S. IgG Fc receptors: evolutionary considera-tions[J]. Curr Top Microbiol Immunol, 2019, 423: 1-11. [3] Stamou M, Grodzki AC, Oostrum MV, et al. Fc gamma receptors are expressed in the developing rat brain and activate downstream signaling molecules upon cross-linking with immune complex[J]. J Neuroinflammation, 2018, 15: 7-29. [4] 刘帆, 苏思, 王涛, 等. 敲除背根神经节Fcgr1减弱类风湿关节炎模型大鼠NF-κB/NLRP3通路活化[J]. 基础医学与临床, 2021, 41: 963-969. [5] 刘帆, 李春艳, 徐鲁斌, 等. Fcγ和Fcε受体在小鼠三叉神经节的表达[J]. 基础医学与临床, 2015, 35: 729-733. [6] Nimmerjahn F, Ravetch JV. Fc gamma receptors: old friends and new family members[J]. Immunity, 2006, 24: 19-28. [7] Fernandez-Vizarra P, Lopez-Franco O, Mallavia B, et al. Immunoglobulin G Fc receptor deficiency prevents Alzheimer-like pathology and cognitive impairment in mice[J]. Brain, 2012, 135: 2826-2837. [8] Kam TI, Song S, Gwon Y, et al. Fc gamma RIIb mediates amyloid-beta neurotoxicity and memory impair-ment in Alzheimer's disease[J]. J Clin Invest, 2013, 123: 2791-2802. [9] Kam TI, Park H, Gwon Y, et al. Fc gamma RIIb-SHIP2 axis links A beta to tau pathology by disrupting phosphoinositide metabolism in Alzheimer's disease model[J]. Elife, 2016, 5: e18691.doi:10.7554/eLife.18691. [10] Ravetch JV, Bolland S. IgG Fc receptors[J]. Annu Rev Immunol, 2001, 19: 275-290. [11] Peress NS, Fleit HB, Perillo E, et al. Identification of FcγRⅠ, Ⅱ and Ⅲ on normal human brain ramified microglia and on microglia in senile plaques in Alzheimer's disease[J]. J Neuroimmunol, 1993, 48: 71-79. [12] Wilcock DM, Rojiani A, Rosenthal A, et al. Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition[J]. J Neurosci, 2004, 24: 6144-6151. [13] Zotova E, Bharambe V, Cheaveau M, et al. Inflammatory components in human Alzheimer's disease and after active amyloid-beta42 immunization[J]. Brain, 2013, 136: 2677-2696. [14] Bard F, Cannon C, Barbour R, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease[J]. Nat Med, 2000, 6: 916-919. |